| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e55532fcc73e6d24f77ace5cc6704875
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_caf3e73ffd76e0dfbb95824b4eb8cce0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f3e34945b9d7ff5d994fc43b2e40d27d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9564c2ceb73afa66c9f83d9ba6ef426a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b2d39290ea135452643afe8b49d0628a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-071
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 |
| filingDate |
2012-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_115d9316140ad3b2be94574580c8e4ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05caab66de910576a937b1b1d7464e78
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0067d582b0f1d327a80be802460e5f07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c73039c35b91ecda48df84b778e8eada
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51122a958b854ba15daa6000f72e71ad |
| publicationDate |
2012-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2012145723-A1 |
| titleOfInvention |
Method for combined conditioning and chemoselection in a single cycle |
| abstract |
A method of radiation-free hematopoietic stem cell (HSC) transplantation comprises administering to a mammalian subject one or two doses of 2 to 10 mg/kg body weight of a purine base analog, such as 6TG as a pre-conditioning step. The method further comprises engrafting into the subject hypoxanthine-guanine phosphoribosyltransferase (HPRT)-deficient donor HSCs within 48 to 72 hours of the pre-conditioning step; and administering to the subject about 1 to 5 mg/kg of the purine base analog every two to four days for two to eight weeks following the engrafting step. The method is performed in the absence of pre-conditioning via radiation. The subject is therefore not treated with myeloablative radiation in preparation for transplantation, and thus the subject is free of myeloablative radiation-induced toxicity. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020139800-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020139796-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4190339-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018094126-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111164211-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10426798-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019100759-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019018383-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109963566-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019018491-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10961537-B2 |
| priorityDate |
2011-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |